Profound Medical Corp.

PROFNASDAQHealthcare● Active

$6.57

$-0.09(-1.35%)

Market Cap$198804245

P/E Ratio—

52W High$8.95

52W Low$3.76

Avg Volume182K

Open$6.68

Beta0.72

Free Cash Flow Financials Revenue

Profound Medical Corp. (PROF) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

PROF · free cash flow · updated Jun 8, 2026

Core FCF metrics

PROF · FCF · TTM · margin & CAGR

Free cash flow was −$53.6M for FY2025 (fiscal year ending 2025-12-31), down 128.5% year-over-year The FCF margin was -327.2%.

FY2025 Free Cash Flow−$53.6M▼ -128.5% YoY

Trailing 12M (TTM)−$39.0Mtrailing 4 quarters sum

FCF Margin-327.2%−$53.6M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

PROF · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$53.3M(0M)−$53.6M▼ 128.5%-327.2%

FY2024−$23.5M(0M)−$23.5M▼ 3.7%-230.7%

FY2023−$22.6M(0M)−$22.6M▲ +12.4%-314.1%

FY2022−$25.8M(0M)−$25.8M▼ 12.4%-386.2%

FY2021−$22.4M(1M)−$23.0M▼ 9.7%-334.0%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

PROF · P/FCF · FCF yield · FCF per share

Profound Medical Corp. (PROF) reported negative free cash flow of −$0.05B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

PROF · cash flow statement · operating / investing / financing

For FY2025, Profound Medical Corp. generated −$53.3M in operating cash flow and spent 0M in capital expenditures, yielding −$53.6M in free cash flow.

Operating Activities

−$53.3M

Cash from core business operations

2025-12-31

Investing Activities

−$0.3M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$57.4M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$53.3M) − |CapEx| (0M) = FCF (−$53.6M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

PROF vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Profound Medical Corp.YOU

PROF

−$53.6M-128.5%-327.2%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Profound Medical Corp. (PROF) reported free cash flow of −$53.6M for FY2025 (fiscal year ending 2025-12-31), down 128.5% year-over-year. The FCF margin was -327.2%.

Profound Medical Corp. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 14 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

PROF free cash flow · 8 questions

Profound Medical Corp. free cash flow was −$53.6M for FY2025, down 128.5% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$39.0M.

PROF free cash flowPROF FCFPROF FCF 2025PROF free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Profound Medical Corp. · Profound Medical Corp. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026